期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 90, 期 5, 页码 662-665出版社
WILEY
DOI: 10.1038/clpt.2011.177
关键词
-
资金
- Instituto de Salud Carlos III
- Spanish Ministerio de Ciencia e Innovacion [BIO2008-02329]
- National Institutes of Health [1R21GM095952-01, 5U54MH084690-03]
- Villum Foundation CDSB
- National Institute of Mental Health's [HHSN-271-2008-00025-C]
The link between cyclobenzaprine (Flexeril) administration and serotonin syndrome (SS) is subject to debate. Establishing such a connection is difficult because of the limited number of case reports available and the almost complete ignorance of its preclinical pharmacology. In this context, evidence is provided here that cyclobenzaprine blocks the serotonin and norepinephrine transporters and binds to another set of five serotonin receptors. SS should be considered when indicative signs occur in the context of cyclobenzaprine use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据